Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Missed Opportunities Punctuate NICE Reform, Says UK Industry

Executive Summary

ABPI calls on UK to address lower investments in new medicines compared with comparable markets.

You may also be interested in...



Pharma Firms Keep A Close Eye On NICE's New HTA Approach In UK

Companies are keen to know how the disease severity modifier and a more flexible approach to uncertainty will be applied to health technology appraisals for drugs in practice. They also want reassurance that there will be consistency in deliberations by NICE’s various committees and advisory groups.

Australian HTA Consults On Discount Rate

PBAC, Australia’s health technology assessment body, is asking for feedback on whether its discount rate – a tool used in economic modelling – is too high.

NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England

Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel